Literature DB >> 31315962

Adjuvant Trastuzumab Therapy: Can We Balance Efficacy and Safety?

Carly C Barron1, Nidhi Kumar Tyagi2, Muhammad Mustafa Alhussein1, Som D Mukherjee2, Peter M Ellis2,3, Sukhbinder Dhesy-Thind2, Darryl P Leong4,3,5.   

Abstract

Trastuzumab is an effective treatment for HER2-positive breast cancer. Current guidelines recommend withholding trastuzumab in patients experiencing a significant asymptomatic decline in left ventricular function. In this commentary, we discuss the survival benefits afforded by trastuzumab juxtaposed against the risk of trastuzumab-mediated cardiotoxicity. It is not known whether the net benefit of continuing trastuzumab in the setting of mild cardiotoxicity outweighs the associated risks. We describe a potential approach undertaken by our group, and others, and call for a randomized trial. © AlphaMed Press 2019.

Entities:  

Keywords:  Breast cancer; Cardiotoxicity; Cardio‐oncology; HER2; Trastuzumab

Year:  2019        PMID： 31315962      PMCID： PMC6853116          DOI： 10.1634/theoncologist.2019-0263

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  30 in total

1.  Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

Authors:  Michael S Ewer; Scott M Lippman
Journal:  J Clin Oncol       Date:  2005-05-01       Impact factor: 44.544

2.  Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes.

Authors:  Y Y Zhao; D R Sawyer; R R Baliga; D J Opel; X Han; M A Marchionni; R A Kelly
Journal:  J Biol Chem       Date:  1998-04-24       Impact factor: 5.157

3.  Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy.

Authors:  Paaladinesh Thavendiranathan; Andrew D Grant; Tomoko Negishi; Juan Carlos Plana; Zoran B Popović; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2012-11-28       Impact factor: 24.094

4.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

5.  Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.

Authors:  Michael S Ewer; Mary T Vooletich; Jean-Bernard Durand; Myrshia L Woods; Joseph R Davis; Vicente Valero; Daniel J Lenihan
Journal:  J Clin Oncol       Date:  2005-11-01       Impact factor: 44.544

6.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

7.  Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.

Authors:  Anthony F Yu; Nandini U Yadav; Anne A Eaton; Betty Y Lung; Howard T Thaler; Jennifer E Liu; Clifford A Hudis; Chau T Dang; Richard M Steingart
Journal:  Oncologist       Date:  2015-08-03

Review 8.  Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.

Authors:  Dorothy M Gujral; Guy Lloyd; Sanjeev Bhattacharyya
Journal:  Breast       Date:  2017-11-01       Impact factor: 4.380

9.  Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Authors:  Chau Dang; Hao Guo; Julie Najita; Denise Yardley; Kelly Marcom; Kathy Albain; Hope Rugo; Kathy Miller; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beverly Moy; John Groarke; Javid Moslehi; Ian Krop; Harold J Burstein; Clifford Hudis; Eric P Winer; Sara M Tolaney
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

10.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983
View more
  1 in total

1.  Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.

Authors:  Katia Khoury; Filipa Lynce; Ana Barac; Xue Geng; Chau Dang; Anthony F Yu; Karen L Smith; Christopher Gallagher; Paula R Pohlmann; Raquel Nunes; Pia Herbolsheimer; Robert Warren; Monvadi B Srichai; Mark Hofmeyer; Federico Asch; Ming Tan; Claudine Isaacs; Sandra M Swain
Journal:  Breast Cancer Res Treat       Date:  2021-01-05       Impact factor: 4.872
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.